AstraZeneca ADR Representing 0.5 logo

AstraZeneca ADR Representing 0.5 Stock

StockStock
ISIN: US0463531089
Ticker: AZN
US0463531089
AZN

Price

Historical dividends and forecast

All dividend data

AstraZeneca ADR Representing 0.5 has so far distributed $1.485 in 2024. The next dividend will be paid on 25.03.2025


$1.034

CHART BY

Frequently asked questions

What is AstraZeneca ADR Representing 0.5's market capitalization?

The market capitalization of AstraZeneca ADR Representing 0.5 is $198.15B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is AstraZeneca ADR Representing 0.5's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for AstraZeneca ADR Representing 0.5 is 31.28. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for AstraZeneca ADR Representing 0.5?

AstraZeneca ADR Representing 0.5's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $4.087. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for AstraZeneca ADR Representing 0.5's stock?

Currently, 30 analysts cover AstraZeneca ADR Representing 0.5's stock, with a consensus target price of $164.75. Analyst ratings provide insights into the stock's expected performance.

What is AstraZeneca ADR Representing 0.5's revenue over the trailing twelve months?

Over the trailing twelve months, AstraZeneca ADR Representing 0.5 reported a revenue of $48.67B.

What is the EBITDA for AstraZeneca ADR Representing 0.5?

AstraZeneca ADR Representing 0.5's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $15.29B. EBITDA measures the company's overall financial performance.

What is the free cash flow of AstraZeneca ADR Representing 0.5?

AstraZeneca ADR Representing 0.5 has a free cash flow of $2.48B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of AstraZeneca ADR Representing 0.5's stock?

The 5-year beta for AstraZeneca ADR Representing 0.5 is 0.39. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does AstraZeneca ADR Representing 0.5 have, and what sector and industry does it belong to?

AstraZeneca ADR Representing 0.5 employs approximately 89,900 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of AstraZeneca ADR Representing 0.5's shares?

The free float of AstraZeneca ADR Representing 0.5 is 1.50B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$198.15B

5Y beta

 
0.39

EPS (TTM)

 
$4.087

Free Float

 
1.50B

P/E ratio (TTM)

 
31.28

Revenue (TTM)

 
$48.67B

EBITDA (TTM)

 
$15.29B

Free Cashflow (TTM)

 
$2.48B

Pricing

52W span
$61.10$88.89

Analyst Ratings

The price target is $164.75 and the stock is covered by 30 analysts.

Buy

24

Hold

5

Sell

1

Information

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

89,900

Biotechnology & Drugs

Health Care

Identifier

ISIN

US0463531089

Primary Ticker

AZN

Knockouts

Join the conversation